John Saia Sells 10,000 Shares of Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH) insider John Saia sold 10,000 shares of the stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $125.08, for a total value of $1,250,800.00. Following the transaction, the insider directly owned 35,950 shares of the company’s stock, valued at $4,496,626. The trade was a 21.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Guardant Health Price Performance

Shares of Guardant Health stock opened at $129.69 on Friday. The business has a 50 day simple moving average of $95.08 and a two-hundred day simple moving average of $99.94. Guardant Health, Inc. has a 12 month low of $38.03 and a 12 month high of $133.97. The stock has a market capitalization of $17.20 billion, a P/E ratio of -38.26 and a beta of 1.48.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Evercore set a $110.00 target price on Guardant Health in a report on Friday, February 20th. Canaccord Genuity Group increased their target price on Guardant Health from $125.00 to $135.00 and gave the company a “buy” rating in a report on Friday, February 20th. Leerink Partners increased their target price on Guardant Health from $170.00 to $180.00 and gave the company an “outperform” rating in a report on Friday, February 20th. Wells Fargo & Company increased their target price on Guardant Health from $120.00 to $125.00 and gave the company an “overweight” rating in a report on Friday, February 20th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a report on Tuesday, April 21st. Nineteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Guardant Health has a consensus rating of “Moderate Buy” and an average price target of $129.79.

Institutional Investors Weigh In On Guardant Health

Several hedge funds and other institutional investors have recently made changes to their positions in GH. Alyeska Investment Group L.P. acquired a new stake in shares of Guardant Health in the third quarter valued at approximately $114,421,000. Price T Rowe Associates Inc. MD increased its holdings in shares of Guardant Health by 33.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock valued at $575,670,000 after purchasing an additional 1,414,441 shares during the last quarter. Norges Bank acquired a new stake in Guardant Health during the fourth quarter worth $128,499,000. Summit Partners Public Asset Management LLC increased its stake in Guardant Health by 674.5% during the fourth quarter. Summit Partners Public Asset Management LLC now owns 851,958 shares of the company’s stock worth $87,019,000 after acquiring an additional 741,958 shares during the last quarter. Finally, Franklin Resources Inc. increased its stake in Guardant Health by 26.1% during the third quarter. Franklin Resources Inc. now owns 2,926,315 shares of the company’s stock worth $182,836,000 after acquiring an additional 606,368 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.